Literature DB >> 22850406

Cerebral blood flow and metabolism of hyperperfusion after cerebral revascularization in patients with moyamoya disease.

Yasuyuki Kaku1, Koji Iihara, Norio Nakajima, Hiroharu Kataoka, Kenji Fukuda, Jun Masuoka, Kazuhito Fukushima, Hidehiro Iida, Nobuo Hashimoto.   

Abstract

In moyamoya disease (MMD), surgical revascularization may be complicated with postoperative hyperperfusion. We analyzed cerebral perfusion and metabolism using positron emission tomography (PET) or single-photon emission computed tomography (SPECT) before and after bypass surgery on 42 sides of 34 adult patients with MMD. In seven cases (16.7%) with symptomatic hyperperfusion, diagnosed by qualitative (123)I-iodoamphetamine (IMP) SPECT, a subsequent PET study during postoperative subacute stages revealed significantly increased cerebral blood flow (CBF) from 34.1 ± 8.2 to 74.3 ± 12.8 mL/100 g per minute (P<0.01), a persistent increase in cerebral blood volume (CBV) from 5.77 ± 1.67 to 7.01 ± 1.44 mL/100 g and a significant decrease in oxygen extraction fraction (OEF) from 0.61 ± 0.09 to 0.40 ± 0.08 (P<0.01). Mean absolute CBF values during symptomatic hyperperfusion were more than the normal control +2 standard deviations, the predefined criteria of PET. Interestingly, two patients with markedly increased cerebral metabolic rate of oxygen (CMRO(2)) at hyperperfusion were complicated with postoperative seizure. Among preoperative PET parameters, increased OEF was the only significant risk factor for symptomatic hyperperfusion (P<0.05). This study revealed that symptomatic hyperperfusion in MMD is characterized by temporary increases in CBF >100% over preoperative values caused by prolonged recovery of increased CBV.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22850406      PMCID: PMC3493997          DOI: 10.1038/jcbfm.2012.110

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  37 in total

Review 1.  Moyamoya disease: recent progress and outlook.

Authors:  Jun C Takahashi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2010       Impact factor: 1.742

2.  Rapid quantitative measurement of CMRO(2) and CBF by dual administration of (15)O-labeled oxygen and water during a single PET scan-a validation study and error analysis in anesthetized monkeys.

Authors:  Nobuyuki Kudomi; Takuya Hayashi; Noboru Teramoto; Hiroshi Watabe; Naoki Kawachi; Youichirou Ohta; Kyeong Min Kim; Hidehiro Iida
Journal:  J Cereb Blood Flow Metab       Date:  2005-09       Impact factor: 6.200

Review 3.  Moyamoya disease: current concepts and future perspectives.

Authors:  Satoshi Kuroda; Kiyohiro Houkin
Journal:  Lancet Neurol       Date:  2008-11       Impact factor: 44.182

4.  Intracerebral hemorrhage after carotid endarterectomy.

Authors:  D G Piepgras; M K Morgan; T M Sundt; T Yanagihara; L M Mussman
Journal:  J Neurosurg       Date:  1988-04       Impact factor: 5.115

5.  Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease: comparative study with non-moyamoya patients using N-isopropyl-p-[(123)I]iodoamphetamine single-photon emission computed tomography.

Authors:  Miki Fujimura; Hiroaki Shimizu; Takashi Inoue; Shunji Mugikura; Atsushi Saito; Teiji Tominaga
Journal:  Neurosurgery       Date:  2011-04       Impact factor: 4.654

6.  Analysis of vasoactivity of local pH, PCO2 and bicarbonate on pial vessels.

Authors:  H A Kontos; A J Raper; J L Patterson
Journal:  Stroke       Date:  1977 May-Jun       Impact factor: 7.914

7.  Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease.

Authors:  Miki Fujimura; Tomohiro Kaneta; Shunji Mugikura; Hiroaki Shimizu; Teiji Tominaga
Journal:  Surg Neurol       Date:  2007-03

8.  Preserved acetazolamide reactivity in lacunar patients with severe white-matter lesions: 15O-labeled gas and H2O positron emission tomography studies.

Authors:  Tomohisa Nezu; Chiaki Yokota; Toshiyuki Uehara; Miho Yamauchi; Kazuhito Fukushima; Kazunori Toyoda; Masayasu Matsumoto; Hidehiro Iida; Kazuo Minematsu
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-18       Impact factor: 6.200

9.  Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited.

Authors:  Colin P Derdeyn; Tom O Videen; Kent D Yundt; Susanne M Fritsch; David A Carpenter; Robert L Grubb; William J Powers
Journal:  Brain       Date:  2002-03       Impact factor: 13.501

10.  Metabolic changes in cerebral cortex, hippocampus, and cerebellum during sustained bicuculline-induced seizures.

Authors:  J Folbergrová; M Ingvar; B K Siesjö
Journal:  J Neurochem       Date:  1981-11       Impact factor: 5.372

View more
  16 in total

1.  Does applying resolution recovery to normal databases confer an advantage over conventional 3D-stereotactic surface projection techniques?

Authors:  Nobuhiro Yada; Hideo Onishi; Masahiro Miyai; Kentarou Ozasa; Takashi Katsube; Keiichi Onoda; Masuo Haramoto; Yasushi Yamamoto; Shuhei Yamaguchi; Hajime Kitagaki
Journal:  Radiol Phys Technol       Date:  2017-02-04

2.  Prominence of Medullary Veins on Susceptibility-Weighted Images Provides Prognostic Information in Patients with Subacute Stroke.

Authors:  X Yu; L Yuan; A Jackson; J Sun; P Huang; X Xu; Y Mao; M Lou; Q Jiang; M Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-29       Impact factor: 3.825

3.  Long-term patency of superficial temporal artery to middle cerebral artery bypass for cerebral atherosclerotic disease: factors determining the bypass patent.

Authors:  Fumihiro Matano; Yasuo Murai; Kojiro Tateyama; Tomonori Tamaki; Takayuki Mizunari; Hideoshi Matsukawa; Akira Teramoto; Akio Morita
Journal:  Neurosurg Rev       Date:  2016-05-04       Impact factor: 3.042

4.  Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone.

Authors:  Hidetoshi Nakamoto; Yasuo Aihara; Koji Yamaguchi; Takakazu Kawamata; Yoshikazu Okada
Journal:  Childs Nerv Syst       Date:  2015-07-24       Impact factor: 1.475

Review 5.  Cerebral oxygen extraction fraction MRI: Techniques and applications.

Authors:  Dengrong Jiang; Hanzhang Lu
Journal:  Magn Reson Med       Date:  2022-05-05       Impact factor: 3.737

6.  Time-of-Flight MR Angiography for Detection of Cerebral Hyperperfusion Syndrome after Superficial Temporal Artery-Middle Cerebral Artery Anastomosis in Moyamoya Disease.

Authors:  K Sato; M Yamada; H Kuroda; D Yamamoto; Y Asano; Y Inoue; K Fujii; T Kumabe
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-03       Impact factor: 3.825

7.  Laser speckle imaging allows real-time intraoperative blood flow assessment during neurosurgical procedures.

Authors:  Nils Hecht; Johannes Woitzik; Susanne König; Peter Horn; Peter Vajkoczy
Journal:  J Cereb Blood Flow Metab       Date:  2013-03-20       Impact factor: 6.200

8.  2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society.

Authors:  Miki Fujimura; Teiji Tominaga; Satoshi Kuroda; Jun C Takahashi; Hidenori Endo; Kuniaki Ogasawara; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-02-22       Impact factor: 2.036

Review 9.  Cognitive Dysfunction Survey of the Japanese Patients with Moyamoya Disease (COSMO-JAPAN Study): study protocol.

Authors:  Yasushi Takagi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-02-20       Impact factor: 1.742

10.  Predicting Cerebral Hyperperfusion Syndrome Following Superficial Temporal Artery to Middle Cerebral Artery Bypass based on Intraoperative Perfusion-Weighted Magnetic Resonance Imaging.

Authors:  Defeng Wang; Fengping Zhu; Ka Ming Fung; Wei Zhu; Yishan Luo; Winnie Chiu Wing Chu; Vincent Chung Tong Mok; Jinsong Wu; Lin Shi; Anil T Ahuja; Ying Mao
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.